Jacobi Capital Management LLC Acquires 107 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Jacobi Capital Management LLC boosted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 8.1% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,425 shares of the biopharmaceutical company’s stock after purchasing an additional 107 shares during the quarter. Jacobi Capital Management LLC’s holdings in Regeneron Pharmaceuticals were worth $904,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in REGN. Marietta Wealth Management LLC increased its stake in Regeneron Pharmaceuticals by 30.2% in the 1st quarter. Marietta Wealth Management LLC now owns 10,778 shares of the biopharmaceutical company’s stock worth $6,836,000 after acquiring an additional 2,501 shares during the last quarter. GAMMA Investing LLC increased its stake in Regeneron Pharmaceuticals by 89,825.0% in the 1st quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company’s stock worth $517,291,000 after acquiring an additional 814,713 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its stake in Regeneron Pharmaceuticals by 3.9% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 25,629 shares of the biopharmaceutical company’s stock worth $16,255,000 after acquiring an additional 955 shares during the last quarter. Sepio Capital LP increased its stake in Regeneron Pharmaceuticals by 33.1% in the 1st quarter. Sepio Capital LP now owns 3,389 shares of the biopharmaceutical company’s stock worth $2,150,000 after acquiring an additional 842 shares during the last quarter. Finally, KBC Group NV increased its stake in Regeneron Pharmaceuticals by 9.4% in the 1st quarter. KBC Group NV now owns 149,440 shares of the biopharmaceutical company’s stock worth $94,779,000 after acquiring an additional 12,793 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

REGN opened at $560.00 on Friday. The business has a fifty day moving average of $564.61 and a 200 day moving average of $579.66. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $1,170.58. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09. The stock has a market cap of $59.35 billion, a P/E ratio of 14.11, a PEG ratio of 1.90 and a beta of 0.35.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The company had revenue of $3.68 billion during the quarter, compared to analysts’ expectations of $3.30 billion. During the same quarter in the previous year, the business earned $11.56 EPS. Regeneron Pharmaceuticals’s revenue was up 3.6% compared to the same quarter last year. As a group, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were issued a dividend of $0.88 per share. The ex-dividend date was Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals’s payout ratio is presently 8.87%.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $850.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, July 23rd. Rothschild & Co Redburn began coverage on Regeneron Pharmaceuticals in a report on Thursday, August 14th. They set a “buy” rating and a $890.00 price target on the stock. Argus lowered Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, June 30th. Citigroup restated a “buy” rating and set a $650.00 price target on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Finally, Wells Fargo & Company lowered Regeneron Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $580.00 price target on the stock. in a report on Friday, August 1st. Three research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $817.67.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.